Financhill
Sell
37

GLAXF Quote, Financials, Valuation and Earnings

Last price:
$16.90
Seasonality move :
-0.27%
Day range:
$16.89 - $17.10
52-week range:
$15.68 - $23.00
Dividend yield:
4.59%
P/E ratio:
21.97x
P/S ratio:
1.76x
P/B ratio:
3.68x
Volume:
18.5K
Avg. volume:
7.3K
1-year change:
-13.24%
Market cap:
$69B
Revenue:
$37.7B
EPS (TTM):
$0.77

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
GLAXF
GSK PLC
$9.5B -- -3.62% -- --
ADAP
Adaptimmune Therapeutics PLC
$8.8M -$0.15 4199.24% -9.44% $2.27
AUTL
Autolus Therapeutics PLC
$3M -$0.24 -61.82% -46.14% $10.45
BDRX
Biodexa Pharmaceuticals PLC
-- -- -- -- $17.97
NCNA
NuCana PLC
-- -$0.09 -- -98.11% $64.50
VRNA
Verona Pharma PLC
$27.4M -$0.21 -- -2.08% $63.50
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
GLAXF
GSK PLC
$16.90 -- $69B 21.97x $0.19 4.59% 1.76x
ADAP
Adaptimmune Therapeutics PLC
$0.58 $2.27 $148.4M -- $0.00 0% 0.82x
AUTL
Autolus Therapeutics PLC
$2.22 $10.45 $590.8M -- $0.00 0% --
BDRX
Biodexa Pharmaceuticals PLC
$4.28 $17.97 $2.5M -- $0.00 0% 3.86x
NCNA
NuCana PLC
$1.14 $64.50 $4.5M -- $0.00 0% --
VRNA
Verona Pharma PLC
$51.89 $63.50 $4.2B -- $0.00 0% --
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
GLAXF
GSK PLC
53.41% 0.453 26.52% 0.52x
ADAP
Adaptimmune Therapeutics PLC
38.4% 4.431 20.51% 3.54x
AUTL
Autolus Therapeutics PLC
-- 3.664 -- 17.97x
BDRX
Biodexa Pharmaceuticals PLC
-- 0.100 -- 1.20x
NCNA
NuCana PLC
-- 1.546 -- --
VRNA
Verona Pharma PLC
47.91% -1.186 5.1% 12.47x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
GLAXF
GSK PLC
$7.3B $245.9M 8.08% 18.89% 2.75% $1.7B
ADAP
Adaptimmune Therapeutics PLC
-- -$14.7M -55.22% -67.8% -38.33% -$54.9M
AUTL
Autolus Therapeutics PLC
-- -$67.7M -80.74% -80.74% -331.28% -$86.3M
BDRX
Biodexa Pharmaceuticals PLC
-- -- -160.77% -160.77% -- --
NCNA
NuCana PLC
-- -$6.6M -- -- -- -$6.4M
VRNA
Verona Pharma PLC
$5.1M -$39.1M -55.17% -74.15% -583.75% -$62.7M

GSK PLC vs. Competitors

  • Which has Higher Returns GLAXF or ADAP?

    Adaptimmune Therapeutics PLC has a net margin of -0.72% compared to GSK PLC's net margin of -43.07%. GSK PLC's return on equity of 18.89% beat Adaptimmune Therapeutics PLC's return on equity of -67.8%.

    Company Gross Margin Earnings Per Share Invested Capital
    GLAXF
    GSK PLC
    70.08% -$0.02 $39.5B
    ADAP
    Adaptimmune Therapeutics PLC
    -- -$0.06 $129.9M
  • What do Analysts Say About GLAXF or ADAP?

    GSK PLC has a consensus price target of --, signalling downside risk potential of --. On the other hand Adaptimmune Therapeutics PLC has an analysts' consensus of $2.27 which suggests that it could grow by 290.87%. Given that Adaptimmune Therapeutics PLC has higher upside potential than GSK PLC, analysts believe Adaptimmune Therapeutics PLC is more attractive than GSK PLC.

    Company Buy Ratings Hold Ratings Sell Ratings
    GLAXF
    GSK PLC
    0 0 0
    ADAP
    Adaptimmune Therapeutics PLC
    4 2 0
  • Is GLAXF or ADAP More Risky?

    GSK PLC has a beta of 0.553, which suggesting that the stock is 44.654% less volatile than S&P 500. In comparison Adaptimmune Therapeutics PLC has a beta of 2.236, suggesting its more volatile than the S&P 500 by 123.631%.

  • Which is a Better Dividend Stock GLAXF or ADAP?

    GSK PLC has a quarterly dividend of $0.19 per share corresponding to a yield of 4.59%. Adaptimmune Therapeutics PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. GSK PLC pays 45.6% of its earnings as a dividend. Adaptimmune Therapeutics PLC pays out -- of its earnings as a dividend. GSK PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios GLAXF or ADAP?

    GSK PLC quarterly revenues are $10.4B, which are larger than Adaptimmune Therapeutics PLC quarterly revenues of $40.9M. GSK PLC's net income of -$75.5M is lower than Adaptimmune Therapeutics PLC's net income of -$17.6M. Notably, GSK PLC's price-to-earnings ratio is 21.97x while Adaptimmune Therapeutics PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GSK PLC is 1.76x versus 0.82x for Adaptimmune Therapeutics PLC. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    GLAXF
    GSK PLC
    1.76x 21.97x $10.4B -$75.5M
    ADAP
    Adaptimmune Therapeutics PLC
    0.82x -- $40.9M -$17.6M
  • Which has Higher Returns GLAXF or AUTL?

    Autolus Therapeutics PLC has a net margin of -0.72% compared to GSK PLC's net margin of -522.15%. GSK PLC's return on equity of 18.89% beat Autolus Therapeutics PLC's return on equity of -80.74%.

    Company Gross Margin Earnings Per Share Invested Capital
    GLAXF
    GSK PLC
    70.08% -$0.02 $39.5B
    AUTL
    Autolus Therapeutics PLC
    -- -$0.31 $582M
  • What do Analysts Say About GLAXF or AUTL?

    GSK PLC has a consensus price target of --, signalling downside risk potential of --. On the other hand Autolus Therapeutics PLC has an analysts' consensus of $10.45 which suggests that it could grow by 365.09%. Given that Autolus Therapeutics PLC has higher upside potential than GSK PLC, analysts believe Autolus Therapeutics PLC is more attractive than GSK PLC.

    Company Buy Ratings Hold Ratings Sell Ratings
    GLAXF
    GSK PLC
    0 0 0
    AUTL
    Autolus Therapeutics PLC
    8 0 0
  • Is GLAXF or AUTL More Risky?

    GSK PLC has a beta of 0.553, which suggesting that the stock is 44.654% less volatile than S&P 500. In comparison Autolus Therapeutics PLC has a beta of 2.049, suggesting its more volatile than the S&P 500 by 104.921%.

  • Which is a Better Dividend Stock GLAXF or AUTL?

    GSK PLC has a quarterly dividend of $0.19 per share corresponding to a yield of 4.59%. Autolus Therapeutics PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. GSK PLC pays 45.6% of its earnings as a dividend. Autolus Therapeutics PLC pays out -- of its earnings as a dividend. GSK PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios GLAXF or AUTL?

    GSK PLC quarterly revenues are $10.4B, which are larger than Autolus Therapeutics PLC quarterly revenues of $10.1M. GSK PLC's net income of -$75.5M is higher than Autolus Therapeutics PLC's net income of -$82.1M. Notably, GSK PLC's price-to-earnings ratio is 21.97x while Autolus Therapeutics PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GSK PLC is 1.76x versus -- for Autolus Therapeutics PLC. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    GLAXF
    GSK PLC
    1.76x 21.97x $10.4B -$75.5M
    AUTL
    Autolus Therapeutics PLC
    -- -- $10.1M -$82.1M
  • Which has Higher Returns GLAXF or BDRX?

    Biodexa Pharmaceuticals PLC has a net margin of -0.72% compared to GSK PLC's net margin of --. GSK PLC's return on equity of 18.89% beat Biodexa Pharmaceuticals PLC's return on equity of -160.77%.

    Company Gross Margin Earnings Per Share Invested Capital
    GLAXF
    GSK PLC
    70.08% -$0.02 $39.5B
    BDRX
    Biodexa Pharmaceuticals PLC
    -- -- $6M
  • What do Analysts Say About GLAXF or BDRX?

    GSK PLC has a consensus price target of --, signalling downside risk potential of --. On the other hand Biodexa Pharmaceuticals PLC has an analysts' consensus of $17.97 which suggests that it could grow by 319.89%. Given that Biodexa Pharmaceuticals PLC has higher upside potential than GSK PLC, analysts believe Biodexa Pharmaceuticals PLC is more attractive than GSK PLC.

    Company Buy Ratings Hold Ratings Sell Ratings
    GLAXF
    GSK PLC
    0 0 0
    BDRX
    Biodexa Pharmaceuticals PLC
    1 0 0
  • Is GLAXF or BDRX More Risky?

    GSK PLC has a beta of 0.553, which suggesting that the stock is 44.654% less volatile than S&P 500. In comparison Biodexa Pharmaceuticals PLC has a beta of 1.460, suggesting its more volatile than the S&P 500 by 46.046%.

  • Which is a Better Dividend Stock GLAXF or BDRX?

    GSK PLC has a quarterly dividend of $0.19 per share corresponding to a yield of 4.59%. Biodexa Pharmaceuticals PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. GSK PLC pays 45.6% of its earnings as a dividend. Biodexa Pharmaceuticals PLC pays out -- of its earnings as a dividend. GSK PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios GLAXF or BDRX?

    GSK PLC quarterly revenues are $10.4B, which are larger than Biodexa Pharmaceuticals PLC quarterly revenues of --. GSK PLC's net income of -$75.5M is higher than Biodexa Pharmaceuticals PLC's net income of --. Notably, GSK PLC's price-to-earnings ratio is 21.97x while Biodexa Pharmaceuticals PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GSK PLC is 1.76x versus 3.86x for Biodexa Pharmaceuticals PLC. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    GLAXF
    GSK PLC
    1.76x 21.97x $10.4B -$75.5M
    BDRX
    Biodexa Pharmaceuticals PLC
    3.86x -- -- --
  • Which has Higher Returns GLAXF or NCNA?

    NuCana PLC has a net margin of -0.72% compared to GSK PLC's net margin of --. GSK PLC's return on equity of 18.89% beat NuCana PLC's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    GLAXF
    GSK PLC
    70.08% -$0.02 $39.5B
    NCNA
    NuCana PLC
    -- -$2.28 --
  • What do Analysts Say About GLAXF or NCNA?

    GSK PLC has a consensus price target of --, signalling downside risk potential of --. On the other hand NuCana PLC has an analysts' consensus of $64.50 which suggests that it could grow by 5557.9%. Given that NuCana PLC has higher upside potential than GSK PLC, analysts believe NuCana PLC is more attractive than GSK PLC.

    Company Buy Ratings Hold Ratings Sell Ratings
    GLAXF
    GSK PLC
    0 0 0
    NCNA
    NuCana PLC
    1 1 0
  • Is GLAXF or NCNA More Risky?

    GSK PLC has a beta of 0.553, which suggesting that the stock is 44.654% less volatile than S&P 500. In comparison NuCana PLC has a beta of 0.973, suggesting its less volatile than the S&P 500 by 2.67%.

  • Which is a Better Dividend Stock GLAXF or NCNA?

    GSK PLC has a quarterly dividend of $0.19 per share corresponding to a yield of 4.59%. NuCana PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. GSK PLC pays 45.6% of its earnings as a dividend. NuCana PLC pays out -- of its earnings as a dividend. GSK PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios GLAXF or NCNA?

    GSK PLC quarterly revenues are $10.4B, which are larger than NuCana PLC quarterly revenues of --. GSK PLC's net income of -$75.5M is lower than NuCana PLC's net income of -$5.9M. Notably, GSK PLC's price-to-earnings ratio is 21.97x while NuCana PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GSK PLC is 1.76x versus -- for NuCana PLC. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    GLAXF
    GSK PLC
    1.76x 21.97x $10.4B -$75.5M
    NCNA
    NuCana PLC
    -- -- -- -$5.9M
  • Which has Higher Returns GLAXF or VRNA?

    Verona Pharma PLC has a net margin of -0.72% compared to GSK PLC's net margin of -763.91%. GSK PLC's return on equity of 18.89% beat Verona Pharma PLC's return on equity of -74.15%.

    Company Gross Margin Earnings Per Share Invested Capital
    GLAXF
    GSK PLC
    70.08% -$0.02 $39.5B
    VRNA
    Verona Pharma PLC
    90.35% -$0.56 $250.5M
  • What do Analysts Say About GLAXF or VRNA?

    GSK PLC has a consensus price target of --, signalling downside risk potential of --. On the other hand Verona Pharma PLC has an analysts' consensus of $63.50 which suggests that it could grow by 22.37%. Given that Verona Pharma PLC has higher upside potential than GSK PLC, analysts believe Verona Pharma PLC is more attractive than GSK PLC.

    Company Buy Ratings Hold Ratings Sell Ratings
    GLAXF
    GSK PLC
    0 0 0
    VRNA
    Verona Pharma PLC
    5 0 0
  • Is GLAXF or VRNA More Risky?

    GSK PLC has a beta of 0.553, which suggesting that the stock is 44.654% less volatile than S&P 500. In comparison Verona Pharma PLC has a beta of 0.400, suggesting its less volatile than the S&P 500 by 60.012%.

  • Which is a Better Dividend Stock GLAXF or VRNA?

    GSK PLC has a quarterly dividend of $0.19 per share corresponding to a yield of 4.59%. Verona Pharma PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. GSK PLC pays 45.6% of its earnings as a dividend. Verona Pharma PLC pays out -- of its earnings as a dividend. GSK PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios GLAXF or VRNA?

    GSK PLC quarterly revenues are $10.4B, which are larger than Verona Pharma PLC quarterly revenues of $5.6M. GSK PLC's net income of -$75.5M is lower than Verona Pharma PLC's net income of -$43M. Notably, GSK PLC's price-to-earnings ratio is 21.97x while Verona Pharma PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GSK PLC is 1.76x versus -- for Verona Pharma PLC. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    GLAXF
    GSK PLC
    1.76x 21.97x $10.4B -$75.5M
    VRNA
    Verona Pharma PLC
    -- -- $5.6M -$43M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Why Is AT&T Stock Dropping?
Why Is AT&T Stock Dropping?

The telecommunications giant AT&T Inc. (NYSE:T) has perhaps surprisingly eclipsed…

Is American Express Stock Going Lower?
Is American Express Stock Going Lower?

American Express Company (NYSE:AXP) has long been a Buffett favorite…

Cigna vs Costco Stock: Which Is Best?
Cigna vs Costco Stock: Which Is Best?

Cigna and Costco don’t usually go hand in hand but…

Stock Ideas

Sell
46
Is AAPL Stock a Buy?

Market Cap: $3.5T
P/E Ratio: 38x

Buy
51
Is NVDA Stock a Buy?

Market Cap: $3.4T
P/E Ratio: 115x

Buy
53
Is MSFT Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 36x

Alerts

Sell
45
QMCO alert for Jan 18

Quantum [QMCO] is down 15.61% over the past day.

Buy
51
QRVO alert for Jan 18

Qorvo [QRVO] is up 14.47% over the past day.

Sell
31
ATEX alert for Jan 18

Anterix [ATEX] is up 11.14% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock